On Monday, Callon Petroleum Company (NYSE:CPE)’s shares declined -6.31% to $6.76.
Callon Petroleum Company (CPE) declared that it has declared a cash dividend of $1.25 per share on its 10.0% Series A Cumulative Preferred Stock (“Series A Preferred Stock”). The dividend will be paid on September 30, 2015 to stockholders of record as of September 14, 2015. The Series A Preferred Stock is presently listed on the New York Stock Exchange under the symbol “CPE.A.”
Callon is an independent energy company focused on the acquisition, development, exploration and operation of oil and gas properties in the Permian Basin in West Texas.
Callon Petroleum Company engages in the exploration, development, acquisition, and production of oil and natural gas properties in the Permian Basin in West Texas. As of December 31, 2014, its estimated net proved reserves totaled 32.8 million barrel of oil equivalent, counting 25.7 million barrels of oil and 42.5 billion cubic feet of natural gas.
Crown Castle International Corp (NYSE:CCI)’s shares dropped -1.51% to $77.57.
Crown Castle International Corp. (CCI) declared that the quarterly dividend on its 4.50% Mandatory Convertible Preferred Stock (“Preferred Stock”) will be paid on November 2, 2015 to holders of record on October 15, 2015. The dividend will be paid in cash at a rate of $1.125 per share of Preferred Stock.
Crown Castle International Corp., together with its auxiliaries, owns, operates, and leases shared wireless infrastructure in the United States and Australia. The company provides towers and other structures, such as rooftops; and distributed antenna systems, a type of small cell network (small cells).
Vital Therapies Inc (NASDAQ:VTL), ended its Monday’s trading session with -2.05% loss, and closed at $4.31.
Vital Therapies, Inc. (VTL), a biotherapeutic company developing ELAD(R), a cell-based therapy targeting the treatment of liver failure, outlined plans for a possible new phase 3 clinical trial designed to confirm ELAD’s safety and efficacy in alcohol-induced liver decompensation (AILD), counting severe acute alcoholic hepatitis, based on trends identified in subset analyses of the Company’s recently accomplished VTI-208 clinical trial.
On August 21, 2015, the Company declared that while its first phase 3 trial, VTI-208, did not reach its primary or secondary endpoints, medically pertinent pre-specified subsets based on age and disease severity did show promising trends toward efficacy. Since then, the Company has conducted a series of pre-specified and post-hoc analyses of subsets of the data in order to determine if there is a basis for designing and implementing a new clinical trial to confirm the efficacy and safety signals identified in these subsets.
Vital Therapies, Inc., a biotherapeutic company, focuses on developing a cell-based therapy for the treatment of acute liver failure in the United States. Its ELAD system is an extracorporeal bio-artificial liver therapy that is in Phase III clinical trials to allow the patients own liver to regenerate to a healthy state, or to stabilize the patient until transplant.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
